Clinical Study

"Tmao" As A Pulmonary Hypertension Marker

Posted Date: Aug 6, 2019

  • Investigator: Arun Jose
  • Specialties: Cardiovascular Disease, Pulmonary Diseases
  • Type of Study: Observational/Survey

Pulmonary arterial hypertension (PAH) is an uncommon vascular disease characterized by elevated pulmonary arterial pressures, which can lead to progressive right heart failure and death. Accurate diagnosis and classification requires right heart catheterization (RHC), and prognosis is primarily driven by the degree of right ventricular failure. Trimethylamine-N-oxide (TMAO), a metabolite of dietary choline produced by intestinal microbes, is known to accelerate atherosclerosis and is an independent risk factor for adverse outcomes in cardiovascular diseases. In both animal and human models of heart failure, TMAO has been associated with dysfunctional ventricular remodeling, myocardial fibrosis, elevated natriuretic peptide levels, platelet dysfunction, and vascular endothelial inflammation. Given that these are also pathological hallmarks of decompensated PAH, it is plausible that TMAO plays a role in the establishment and progression of pulmonary vascular disease. To our knowledge, no study to date has examined the association between serum TMAO and the presence or severity of PAH, or value of TMAO as a biomarker in PAH . The purpose of this study is to investigate if TMAO levels can predict the presence or severity of PAH in patients undergoing diagnostic RHC.


All Adult Patients With Pulmonary Hypertension Receiving Care At The Uc Ph Clinic Getting A Right Heart Catheterization May Be Eligible For Enrollment.


Pulmonary Hypetension

For More Information:

Arun Jose

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.